Bicara Therapeutics (BCAX) Assets (2023 - 2026)

Bicara Therapeutics (BCAX) has 4 years of Assets data on file, last reported at $553.6 million in Q1 2026.

• For the quarter ending Q1 2026, Assets rose 15.8% year-over-year to $553.6 million; the trailing twelve-month figure through Mar 2026 stood at $553.6 million (up 15.8% YoY), and the FY2025 full-year result was $431.0 million, down 15.49% from the prior year.
• Assets for Q1 2026 stood at $553.6 million, up from $431.0 million in the prior quarter.
• Across five years, Assets topped out at $553.6 million in Q1 2026 and bottomed at $234.0 million in Q4 2023.
• The 4-year median for Assets is $465.8 million (2025), against an average of $451.1 million.
• The widest annual swing landed in 2024, when Assets surged 117.96%; it then declined 18.98% in 2025.
• A 4-year view of Assets shows it stood at $234.0 million in 2023, then soared by 117.96% to $510.0 million in 2024, then declined by 15.49% to $431.0 million in 2025, then increased by 28.45% to $553.6 million in 2026.
• The last three Assets figures came in at $553.6 million (Q1 2026), $431.0 million (Q4 2025), and $424.7 million (Q3 2025), per Business Quant data.

Peer Comparison